Open access peer-reviewed chapter

Management of Nasal Silicone Granuloma

Written By

Ago Harlim

Submitted: 19 January 2019 Reviewed: 02 June 2019 Published: 22 July 2019

DOI: 10.5772/intechopen.87188

From the Edited Volume

Cosmetic Surgery

Edited by Yueh-Bih Tang

Chapter metrics overview

1,107 Chapter Downloads

View Full Metrics


The use of silicone as filler material has been banned by the FDA. Nevertheless, there are still some risks of using topical silicone, particularly cosmetic products that contain silicone. Bioavailability of silicone in skin tissues and long-term complications of silicone use in cosmetic products must be evaluated for safety reasons. Silicone can penetrate to the skin by injection. Because of economic issues and the rarity of medical grade silicone, various developing countries use industrial silicone, which results in even more complications. Patients with liquid silicone injected to their nose will usually visit a doctor after experiencing complication issues such as granuloma, edema, and redness with telangiectasia. Usually the patients want to remove the silicone and treat the complication. Unfortunately, silicone is difficult to be removed completely. Some complications are difficult to treat. To handle this complication issue, the doctor has to create a specific design of nose implant, perform curettage, or remove silicone and granuloma, and then a laser treatment and steroid injection will be performed.


  • silicone
  • skin
  • topical
  • nasal implant
  • laser

1. Introduction

Silicone injection has been used since 40 years ago, and at that time, many problems occurred such as migration, inflammation, and granuloma. In 1992, the FDA prohibited silicone injection for cosmetic use [1]. In addition to injection, silicone may be introduced into our body or skin through food intake and cosmetic. Silicone has been widely used in daily cosmetics. Nowadays, due to technology advances, topical drugs can pass through skin barrier and can be penetrated into the skin, which has become a great concern as it may induce granuloma formation. There are relatively very few studies that have been done on silicone concentration in the normal skin.

A study conducted by Harlim in 2018 found that a normal skin contained silicon. The study was performed by taking skin samples from normal subjects and those with face-lift procedure and subsequently compared those samples using the same criteria with the control group, which included skin samples of subjects that had received silicone injection, and the study found granuloma formation. The study found an average amount of silicon level of 44.07 ± 75.86 μg/g in patients with normal skin, while in patients with granuloma, they found 38 times greater silicon level (1709.21 ± 1851.72 μg/g) [2].


2. Silicone

Injectable-grade silicone for medical use has been manufactured widely since the element has been known for its stable and inert characteristics [3, 4]. It includes the use of silicone oil, which has been utilized in the treatment of complicated retinal detachment and heavy silicone oil tamponade. The treatment seems to offer promising results, particularly on improving visual acuity as well as great results on some anatomical parameters; however, there are some concerns as it may cause several complications such as cataract, increased ocular pressure, heavy silicone oil emulsification, and mild inflammatory reaction [5, 6, 7].

Injectable-grade silicone has also been widely used in the form of silicone oil injection. Some studies have suggested that it may have an essential role in reducing the risk of developing diabetic foot ulcer due to its pressure-reducing properties; therefore, it can maintain plantar tissue thickness and alleviate symptoms of diabetic foot ulcer, which may be associated with foot biomechanics [8, 9].

Although it brings advantages, silicone injection may still develop some complications, either local or systemic complications. Local complications may include formation of palpable nodule surrounding injection site, arthralgia, fatigue, electrical neuropathy, and electrical sensation [10], while systemic complications may also occur in the form of lymphadenopathy, renal disease, and hepatic disease. It indicates that the injected silicone can migrate from injection site to other organs causing local and systemic complications. An animal experimental study in mouse model may explain the pathogenesis of such complications. The study has demonstrated that macrophage of skin tissue may engulf the injected silicone and the silicone may be distributed through lymphatic circulation, ultimately causing accumulation in lymph nodes, adrenal glands, and the kidney, liver, and spleen as well as granuloma formation in the skin [11]. Complications due to silicone injection, particularly the granuloma formation may be dose-dependent. A study by Harlim has demonstrated that granuloma formation could be developed when there is a large amount of silicone exposure as the study only found a low level of silicone without any granuloma formation in the normal skin (Figure 1) [2].

Figure 1.

The level of silicon (Si) in normal subjects who had never received silicone injection (never injected) and in subjects with granuloma who had received silicone injection. (cited from A Harlim, et all) [2].

Cultural changes have been encouraging people to pursue their passion on beauty and youth; therefore, cosmeticology has been rapidly growing. With technological advances, more mixed drug ingredients have been added to cosmetic products in order to beautify their customers. Thus, it may indirectly increase the use of topical cosmetics that usually contain silicone; therefore, it will lead to increase silicone uptake to the skin. It has raised a concern that the prolonged and continuous use of cosmetics will cause granuloma formation and other chronic inflammatory effects.


3. Dietary intake and silicon

Aside from medical use, silicon has also been used in food industry, cosmetics, and pharmaceutical industries. Our data shows that the silicon levels in gastrointestinal medications (e.g., antacids), mineral water, and soda drinks are 44.1, 25.6, and 2.91 μg/g, respectively. It can be said that there are many routes for administering silicon into our body. The average daily intake of silicon for European and North American populations is 20–50 mg/day. In China and India, the daily intake of silicon is larger that may reach as many as 140–200 mg/day, in which wheats, fruits, and vegetables are the greatest producers [12].

A research institution of healthy aging and nutrition in the United Kingdom has recently reported a strong correlation between silicon in dietary intake and the health of bone and connective tissue. Therefore, it can be assumed that the correlation is associated with collagen synthesis and/or stabilization of mineral matrix, i.e., silicone intake may affect bone density [13].

Another study, which is an animal experimental study, has demonstrated that there is no evidence of silicon accumulation in silicon consumption. Silicon can be eliminated through digestion process and can be found in feces (93–97%), urine (0.001–0.22%), and expired air (0.01–0.02%) [3]. It indicates that silicon is a stable element and at certain degree it can be resistant to digestive enzymes including gastric acid; therefore, it seems that silicon is not accumulated in the gastroinstestinal system.


4. Silicone in cosmetics

Beauty products for face, hair, and cosmetics may have high silicone content, in which it will be accumulated in the skin tissue. When a topical beauty product containing silicone is applied to the skin, the elastomeric particles of silicone will absorb various liquids including emollient and oil; therefore, silicone is used in skin care product as vehicle (carrier) of active ingredient for the skin or as oil control product of the skin [4, 5].

Types of silicone that are commonly used in cosmetic products:

  • Dimethicone—clear, inert, liquid solubility depends on the length of polymer backbone ranging in thickness from watery consistency to thick.

  • Dimethicone copolyol—silicone that contains an —OH group; therefore, it is more water-soluble resulting in easier incorporation into water-based formulations and also reduces the “slip effect” of the silicone.

  • Cyclomethicone—the shortest cyclic molecule, which has many similarities with dimethicone except it can evaporate, while dimethicone cannot.

  • Cyclo-dimethicone—a combination of dimethicone and cyclomethicones.

The great use of silicones in cosmetic product may increase the risk of accumulation of the substance in our body, particularly in the facial skin. No clear evidence has been found on the bioavailability and concentration of accumulated silicone in topical uses.


5. Granuloma: definition

Granuloma is a foreign body reaction against foreign substances that enter the skin. Granuloma occurs due to continuous or chronic inflammation against foreign substances. Silicone is a foreign substance in the body, which will be encapsulated by the body. Datia cells (giant cells) will encapsulate silicone material, and therefore inflammatory mediators cannot perform phagocytosis, which results in continuous inflammation and causes side effect. The encapsulated material has poor vascularization; therefore, it may potentially induce infections [6].


6. Classification and etiology

There are many kinds of granuloma classification; however, the common classifications are those which have been adjusted to the etiologies [7, 8]. Granuloma formation may occur due to various factors such as biologic, chemical, and physical irritative agents [7]. Classification based on clinical, etiological, and histopathological features can be categorized further into infection, vasculitis, immunological aberration, leukocyte oxidation deficiency, hypersensitivity, chemicals, or neoplasma [14, 15]. Table 1 presents classification of granuloma based on etiology [8].

InfectionsImmunological aberration
HistoplasmaCrohn’s disease
CoccidioidesPrimary biliary cirrhosis
BlastomycesGiant cell arteritis
SporothrixPeyronie’s disease
CryptococcusLangerhans’ granulomatosis
Hepatic granulomatous disease
Immune complex disease
Interferon-δ-receptor deficiency
Vasculitic granulomatosis
ToxocaraNecrotizing sarcoidal
SpirochaetesPolyarteritis nodosa
T. PallidumBronchocentric
T. carateumSystemic lupus
T. pertune
MycobacteriaLeukocyte oxidase defect
M. tuberculosisChronic granulomatous
M. lepraedisease of childhood
M. kansasii
M. marinumHypersensitivity pneumonitis
M. avianFarmers’ lung
BCG vaccineBird fanciers’
Mushroom workers’
BacteriaSuberosis (cork dust)
YersiniaMaple bark strippers’
Paprika splitters’
Other infectionsCoffee bean
Cat-scratchSpatlese lung
NeoplasiaFibrosing alveolitis
CarcinomaWhipple’s disease
ReticulosisPyrexia of unknown origin
DysgerminomaCancer chemotherapy
Reticulum cell sarcomaChalazion
Malignant nasal granulomaSebacous cyst
ChemicalsSea urchin spine injury
SilicaBlau’s syndrome

Table 1.

Classification of granulomatous disorders (cited from James DG, Wiliams WL) [8].


7. Silicone granuloma

Silicone granuloma is a foreign body granuloma, which is characterized by the presence of multinuclear Datia cells and macrophages surrounded by lymphocytes and infiltrates of neutrophils. The granulomatous histological lesion caused by silicone varies depending on the type of silicone.

Tissue reactions to silicone gel or liquids are characterized by the formation of silicone granuloma with cystic space containing foreign body [9]. The irregular surface of silicone cannot be phagocytosed completely by macrophage. Datia cells are formed due to “frustrated” macrophages. Microspheres in the size of less than 15 microns will be phagocytosed and transferred to the lymph node, while those with big size and nonabsorbable polymer will be encapsulated by fibrotic tissue [10].

Datia cell is essential in tissue response to silicone as seen in Figure 2, in which the Datia cell is phagocytosing the silicone. It appears that although the Datia cell cannot eliminate the silicone, it would produce fragmented silicone into smaller pieces. Within a month, the silicone will be in the size of 20–100 microns [11]. However, it still cannot be completely phagocytosed, and ultimately it will be encapsulated by fibrotic tissue.

Figure 2.

Results of histopathological examination (HE 400× magnification) in one of study subject. There is a Datia cell (arrow), which is phagocytosing silicone (S) and is trying to destroy it into smaller pieces (sk) [1].

In general, silicone granuloma can be categorized into three phases according to the natural history of our immune response, which are mild inflammatory phase, i.e., stage 1; inflammation with datia cells, i.e., stages 2, 3, 4, and 5; and tolerance phase with fibrosis, i.e., stages 6 and 7 (Figure 3).

Figure 3.

Stadium 1, moderate reaction with a few inflammatory cells. Stadium 2, inflammatory cells with one or two Datia cells. Stadium 3, inflammatory cells with more than two Datia cells and <50% fibrotic area. Stadium 4, inflammatory cells with more than two Datia cells and >50% fibrotic area. Stadium 5, inflammatory cells with one Datia cell and >50% fibrotic area. Stadium 6, <50% fibrotic area with no Datia cell. Stadium 7, >50% fibrotic area with no Datia cell. (cited from A Harlim, et all) [11].

According to Harlim in 2018, histopathological features of silicone granuloma can be categorized into seven stages, which are: [11]

  1. Stadium 1, moderate reaction with a few inflammatory cells

  2. Stadium 2, inflammatory cells with one or two Datia cells

  3. Stadium 3, inflammatory cells with more than two Datia cells and <50% fibrotic area

  4. Stadium 4, inflammatory cells with more than two Datia cells and >50% fibrotic area

  5. Stadium 5, inflammatory cells with one Datia cell and >50% fibrotic area

  6. Stadium 6, <50% fibrotic area with no Datia cell

  7. Stadium 7, >50% fibrotic area with no Datia cell


8. Diagnosis

Granuloma is a form of localized nodular inflammation, which is found in tissues [7]. On examination, there is a tumor-like mass or node of granulation tissue with active fibroblast growth and capillaries that contain epithelial-like macrophages surrounded by mononuclear cells, lymphocytes, and sometime multinucleated Datia cells present at the central core of granuloma [16].

On clinical point of view, silicone granuloma is characterized by the presence of complications of silicone. There are usually granuloma nodes, migrating silicone, wider nose, and signs of inflammation such as redness and swelling depending on the stage (Figure 4).

Figure 4.

Granuloma due to nasal silicone injection. The photograph shows granuloma node, migrating silicone, wider nose, and signs of inflammation such as edema and redness.


9. Management

The management of silicone-induced granuloma is often difficult due to migrating silicone and some of the silicone penetrating into the skin reaching the epidermis. In general, the management of granuloma can be categorized into two, i.e., surgical and pharmacological treatments. The management of nasal silicone granuloma is adjusted for the occurring complications. We must remove granuloma, which is under the skin; afterward, we perform excision of the excessive skin or implant insertion, creating a firmer and cosmetically more attractive skin. Remaining fibrosis or granuloma can be treated using steroid injection, and laser therapy is performed for redness.


10. Recommendation for surgical care

Granuloma formation occurs due to the presence of foreign body. Skin granuloma will cause a cosmetic problem; therefore, it should be removed.

11. Preoperative preparation

The preoperative preparation is similar to all kinds of skin surgery. A consultation prior to surgical procedure is necessary so that the doctor can perform both physical and psychological evaluation for the candidate. The patient should be informed about surgical procedure and the result may not be perfect as clean silicone injection can never be performed and there is a possibility of swelling. Patients with extreme high expectation will file their complaints in the future.

During the consultation, we must find out about coagulation disorder, either primary or secondary, either due to medication of pharmacological treatment or supplementation. The patients are advised to avoid food or medication that may prolong the bleeding time within 1 or 2 weeks prior to the procedure such as anticoagulants, aspirin, ginseng, garlic, cod liver oil, anticholesterol agent, vitamin E, warfarin, and Ginkgo biloba.

Curettage procedure of nasal silicone granuloma is similar to skin graft procedure, in which the covering skin must be viable. On curettage, the skin will be thinner, and it can be necrotic if there is poor vascularization. Other issues that should come into our consideration are alcohol intake, smoking habit, metabolic disorder, and poor nutrition. Blood pressure and diabetes mellitus must be well-controlled [17, 18, 19].

12. Informed consent

When a skin surgeon decides to perform a surgical procedure, both doctor and patient must consequently understand the impact, risk, and advantages of the procedure. First, the doctor needs to explain the diagnosis and the procedure that will be performed. Treatment of nasal silicone injection is a combination of medical therapy and cosmetic procedure because when it is left untreated, there will be changes such as migration, granuloma, and continuous inflammation. The risks and the advantages of the procedure should be emphasized. Moreover, the procedure during the surgery and the expected result after surgery need to be explained. Possible risks that may develop such as infection and its prevention including the use of antibiotics must also be explained. Patients must know other probable risks such as bleeding, crooked nose, wound scar that probably occurs, asymmetrical nostrils, an implant impression on the skin, granuloma or fibrosis that cannot be cleaned up, persistent redness of skin color, and other modalities of treatment that need to be carried out after the surgical procedure. It should also be explained that the results probably may be imperfect, particularly for patients with unrealistic wish. Results of discussion and patient’s consent are written on an informed consent form, which is subsequently signed by the doctor and patient.

13. Technique and procedure

Every granuloma in the skin that causes cosmetic problem must be removed. Granuloma at inflammatory phase must also be removed to prevent the extension of inflammation. Local or general anesthesia could be used for procedures of skin excision, granuloma curettage, or installation of nasal implant. Instruments that must be prepared included minor surgery set, which can be equipped with curettage kit for cases that need curettage.

14. Preoperative planning

The management of silicone-induced granuloma depends on the affected area; however, basically a doctor will first make a design planning. Next, the doctor will perform procedures according to the design or images and following the plan that has been discussed with the patient.

Depending on the occurring complication, we evaluate whether we need to remove the excessive skin from the nasal columella or should only perform curettage and subsequently install a nasal implant.

Mark the area that will be excised and the protruding granuloma on the dorsal of the nose; therefore, during the surgery we emphasize on the location where the curettage will take place. If we plan to place a solid nasal implant, then we need to make a midline to ensure the implant stays straight when the swelling occurs due to anesthetic drugs.

Depending on the problem, when the nasal dorsum has become wider along with inflammation and the damaged skin, an elliptical vertical excision can be performed on it (Figure 5).

Figure 5.

Elliptical excision of granuloma on the nasal skin.

During silicone injection, it is common to have a wider and descending skin at the area of nasal columella due to migration of silicone injection, which always run downward from the nose; therefore, a skin excision can be performed at lateral and dorsal areas of the nasal columella (Figure 6).

Figure 6.

Design of excision procedure to remove the excessive skin at columella area.

15. Technique

After we have planned the management to overcome nasal problems, we subsequently transfer the plan into preoperative design images and subsequently perform an incision or excision following the plan.

16. Design of nasal implant

In some cases that require implants, the nasal implant is first carved before an excision is performed. Solid implant that has been commonly used is the L-shaped solid implant; however, other kinds of solid implant can also be used.

In making an implant, there are some guidelines on facial esthetics and architectural balance that should be considered.

The face can be divided into three zones with identical width. The first includes a horizontal line from the hairline to the eyebrow; the second horizontal line is from the eyebrow to the nasal base and menton; and the third horizontal line is the line from the nasal base to the end border of the chin.

The association between the lips and chin should be evaluated. The chin projection is determined by a vertical line drawn from a point of one and a half ideal length of the nose to the part of vermillion of the upper lip. The lower lip cannot be more than 2 mm posterior to this line. The position of chin varies extremely depending on sex. In women, the position is slightly posterior to the lower lips, while in men the position of the chin is in-line (Figure 7) [20, 21].

Figure 7.

Guidelines on measuring facial beauty and architectural balance.

The implant is carved or made prior to anesthetic procedure following the guidelines of architectural balance and problems of nasal silicone granuloma as well as the patient’s preferences. For nasal silicone granuloma cases, L-shaped nasal solid implant is used, and part of the nasal bridge is shaved so that it becomes slender since patients with granuloma due to silicone injection usually have wider nose and they want the nose become slender (Figure 3).

The height or the length of the implant is the midline border between the eye and eyebrow up to the nose. The crus of the implant must be measured following the base of columella to the nose. Usually, the crus is made straight so that it can elevate the descending skin caused by silicone injection (Figures 8 and 9).

Figure 8.

L-shaped solid silicone implant. The edge is shaved so it becomes slender.

Figure 9.

Patients with silicone injection usually have wider columella area since liquid silicone will migrate downward due to gravity. Therefore, we have to remove the excessive skin of the lateral and the dorsal columella and place the implant to create a straight nose.

Incision is always made on a hidden area and follows the contour of Langer’s line. The excision is made following preoperative design image, which is an elliptical excision on the nasal dorsum (Figure 5); the procedure is generally performed when the condition is very severe with inflammation and the skin is wrinkled and extremely wider. The risks of the procedure are the formation of thin vertical scar line on the nasal dorsum and dog-ear phenomenon at the end of excision. An accurate calculation before surgery is essential. It is suggested that the skin removal should not be too wide to prevent dog-ear phenomenon or we can place a nasal implant so that it seems firm and creates a better look. Excision can also be made on the area adjacent to excision cut in order to reduce granuloma around the lateral nose. The skin superior to the granuloma must be thick enough to maintain vascularization and a viable skin. Many patients do not want any lengthy scar along their nose; therefore, the management of nasal silicone granuloma only includes curettage, placement of implant, and excision of the excessive skin at columella area.

After the patient received anesthetics using lidocaine or xylocaine without adrenalin, we perform a skin excision at the columella area and remove the excessive skin on the lateral and dorsal columella; afterwards, we perfom undermining procedure inferior to the granuloma using a curved clamp starting from the nasal dorsum area to the nasal bridge near the glabella and lateral of nose depending on the occurring problem. Next, curettage is performed to remove the granuloma. The skin superior to it must be thick enough and well-vascularized. In cases with remaining granuloma with thick fibrosis and those with difficulty in curettage, other modalities should be performed after surgical recovery period such as steroid injection.

To create a good-shaped nose, we remove the excessive skin at the columella area, and at the nasal bridge, we can place an implant so that the skin is firmer and the shape is cosmetically better. Nasal silicone implant is placed under the nasal skin at the curettage area, which has been previously occupied by silicone granuloma.

We can perform curettage to remove silicone and granuloma. In order to create a better superior nasal tip so that the nose seems straighter, we have two choices. The first choice is that we can place the implant under the skin, and at the area, the curettage is performed; or we can put sutures at the lateral area of superior tip of the nose from lateral columella with opposite direction as presented in the following video.

17. Postoperative management

  1. Use nasal splint or gauze for a week to prevent splint displacement.

  2. Prescribing antibiotics for 5–7 days.

  3. Prescribing analgetics every 4–6 hours as necessary.

  4. Prescribing anti-inflammatory drugs for 5–7 days.

  5. Normal saline solution for the nose to overcome postsurgical nasal congestion.

  6. To reduce swelling, apply cold compress to periorbital within the first 48 hours.

  7. When sleeping, the patient should keep the head elevated approximately 45°.

  8. If there is a seroma, we can remove it by suctioning using syringe during the follow-up visit.

  9. Avoid any trauma for 2 weeks.

  10. Remove the stitches on day 10–14.

  11. Have a normal diet, but avoid foods that cause excess lip movement such as apples and corn on the cob for 2 weeks after surgery (Figure 10).

Figure 10.

Patients with silicone injection usually have wider columella area (a). After the excessive skin of the lateral and the dorsal columella are removed and the implant is placed, the columella area will be more slender, thus shaping a straighter nose (b).

18. Adjunctive therapy to overcome other complications

The principle of therapy in managing patients with granuloma due to silicone injection is preventing the development of inflammation as it will cause extention of damage.

Evacuation of silicone-induced granuloma should be performed since the liquid silicone in the tissue is persistent and will continuously induce immune response. Although the granuloma has been excised, the remaining silicone, which has migrated to all direction and has been absorbed in the skin, cannot be removed, and therefore, it may cause recurrent granuloma. The remaining inflammation, both granuloma and fibrosis, requires further treatment.

For granuloma or fibrosis that cannot be removed by surgical procedure, other modalities are required to treat the remaining fibrosis and inflammation that can still be seen on the skin, i.e., skin redness and telangiectasia.

19. Fibrosis and remaining granuloma

Some case reports suggest that to treat silicone-induced granuloma, intralesion injection can be used as well as topical treatment of pimecrolimus, which is applied two times daily for 3 months. Topical imiquimod can be used for 8 weeks as well as minoxillin, allopurinol, and oral prednisone at the dose of 30 mg/day [22, 23]. Results of those treatment have not been satisfying although intralesion injection of triamsinolone is more significant for treating the occurring inflammation [24].

Granuloma and remaining fibrosis may also be treated with subdermal injection of triamcinolone acetonide at a dose of 10 mg/ml or a combination of triamcinolone acetonide and 5-fluorouracil. Steroid injection can be performed at the earliest within 2 weeks after wound closure.

The injection is performed once or twice weekly as many as five to seven times. The dose depends on the amount of remaining granuloma and fibrosis, and usually it is at dose of 0.2–0.4 cc per injection.

Etanercept, which works on TNF-α receptor and Fc-IgG1 binding, has been reported providing good result for silicone granuloma [25, 26, 27]. The administration of this drug at the dose of 50 mg twice weekly or 25 mg of subcutaneous injection two times a week has offered relatively satisfying results [27].

20. Redness on the nasal skin

When the silicone has entered into the skin, it can cause granuloma due to chronic inflammation. Although the granuloma has been removed, the remaining inflammation, e.g., redness on skin, still exists. One of them is redness due to neovascularization such as telangiectasia due to silicone block in the skin.

Nasal redness and telangiectasia can be reduced using laser treatment. To utilize laser for treatment, we need basic knowledge about the use of laser.

There are three characteristic properties of laser light: monochromatic light. The light contains only a single wavelength, which is determined by the magnitude of released energy. The light has coherent characteristic, and the photon moves regularly as it has the same wavefront to one another.

The light is highly directional. A laser light has a very tight beam that is dense, strong, and concentrated. The three abovementioned characteristics can be achieved since there is a process of stimulated emission.

A light is part of the spectrum of electromagnetic radiation with an energy known as photon, while the molecule that absorbs the light is called chromophore. The energy is transferred from photon entering into chromophore in the skin. After the energy is absorbed, the light can initiate photochemical reaction, heat up the tissue to the state of coagulation or evaporation, and can destroy or detonate tissue structure through extremely rapid localized heating.

Laser is an instrument that produces light beam with certain wavelength or color that is very parallel and coherent. The light wavelength is absorbed maximally by the component of the treated skin. When the absorption characteristics of the target tissue accurately meet the most ideal wavelength, it will develop maximum specificity of laser to tissue interaction.

The mechanism of action of laser is consistent with specific chromophore with certain wavelength. There are three major chromophores in the body, which are hemoglobin, pigment, and water. For redness and telangiectasia cases, we use laser, which mostly works on hemoglobin. The wavelength of laser must be adjusted to the existing problem. Laser light enters the target area on the skin, and subsequently the light is absorbed by specific blood vessel in the skin causing damage on the target blood vessel that contains hemoglobin without injuring the surrounding tissue. We need basic knowledge to perform safer use of laser [28, 29].

In addition to chromophore, we also need to know about thermal relaxation time (TRT). TRT is the time it takes for a target substance to cool half the temperature needed for heating the target without increasing the temperature of surrounding tissue. In order to perform safe procedure, the fluence of a laser pulse must be high enough to heat the target, and the pulse duration must be shorter than the TRT of the target. Each target has its own TRT. For blood vessel, which has TRT up to microseconds, we need long pulse duration; therefore, we should use the long-pulse Nd:Yag laser instead of the QS Nd:Yag laser, which only has pulse duration of nanoseconds. QS Nd:Yag is usually used for tattoo removal.

Laser works based on the selective photothermolysis principle. In this case, it can be used for hemoglobin to treat redness due to the silicone injection. Some lasers that can also be used are vascular laser such as pulse dye laser (PDL) or long-pulse Nd:Yag [30, 31].

A previous study shows that pulse dye laser (PDL) with a wavelength of 595 nm can be used for vascular disorder such as angioma, port-wine stain, rosacea, or other vascular disorders at the dose of 6–8 J/cm2 every 8 weeks. To prevent side effect, cooling is always performed before laser procedure; some instruments have already had a cryo cooler. The side effects of post-PDL laser treatment are bruising, crust, post-inflammatory hyperpigmentation, particularly for skin types 3–6 according to Fitzpatrick classification [30].

Long-pulse Nd:Yag laser with a wavelength of 1064 nm is also good for treatment of vascular disorder. For deeper vascular disorders and those abnormalities in patients with dark skin types such as the Fitzpatrick skin types 3–6, the instrument will give greater advantages because the 1064 nm wavelength is usually used for pigment chromophore. In contrast, the instrument also has lower safety limit as poor cooling process can often burn the skin. Side effects of long-pulse Nd:Yag laser are bullae, crust, post-inflammatory hyperpigmenta-tion, and scar [31, 32].

In utilizing the long-pulse Nd:Yag laser, we need to set the pulse duration. In silicone-induced disorders, there will be redness on the skin, and one of them is telangiectasia that requires higher dose but lower pulse duration (Figure 11).

Figure 11.

Illustration of a patient’s skin due to complication of silicone injection on the nasal skin; there is an erythematous skin, and among them, there is a telangiectasia (a). After Nd:Yag laser, the reddish skin and telangiectasia are reduced (b).

In erythematous skin cases, the long-pulse Nd:Yag laser with a wavelength of 1064 nm, at dose of approximately 100 J, spot size of 4, and pulse duration of 10 ms, can be used. For telangiectasia, the power is approximately of 180 J, a spot size of 2, and pulse duration of 5 ms. Sufficient cooling before and after laser procedure should be done, either by using ice pack, air cooling, cryo, or other methods. The laser treatment should be started at a low dose, and the dose is increased gradually for each visit until a change can be observed. The target does not diminish instantly; the color does not always change rapidly; sometimes it only becomes paler.

21. Pitfalls and the management

For a necrotic skin, skin excision on the nasal dorsum is usually done, which is followed by curettage of the surrounding area. We usually clean up the necrotic area and performed wound care, open wound healing enhanced with topical medication that can induce granulation, laser diode, PRP, or others. In general, the wound will heal in 2–3 months.

Excessive granuloma or extensive fibrotic area occurs due to a hard necrotic skin, which creates difficulty in curettage. We can repeat the curettage procedure after a few months, which is followed by steroid injection. For less good-looking nose, excision procedure of the remaining skin can be repeated.

The skin can be burnt due to laser treatment for removing redness or telangiectasia for nasal area. Sufficient cooling before and after laser procedure should be done immediately. Sometime a strong topical steroid such as clobetasol propionate can be applied directly onto the skin after the laser procedure.

22. Conclusion

Treatment for silicone-induced granuloma is not easy because the silicone that enters the skin can migrate and a lot of modalities are required to treat complications. Although the use of silicone injection has been prohibited, we still need to be cautious because there are many cosmetics containing silicone, especially with technological advances that can make the silicone readily absorbed by the skin.


  1. 1. Peters W, Fomarsier V. Complication from injectable material used for breast augmentation. The Canadian Journal of Plastic Surgery. 2009;17(3):89-96
  2. 2. Harlim A, Aisah S, Sihombing R. Silicon level in skin tissues of normal female individuals. Journal of Pakistan Association of Dermatologists. 2018;28:2
  3. 3. Eighteenth Report of the Joint FAO/WHO Expert Committee on Food Additives, Wld Hlth Org. Techn. Rep. Ser., No. 557. FAO Nutrition Meetings Report Series, No. 54. 1974. Available from:
  4. 4. Liles DT, Lin F. Silicon Elastomeric Particles in Skin Care Applications, Chapter 11. Vol. 1053. Science & Technology Department; 2010. pp. 207-219
  5. 5. Nair A, Jacob S, Al-Dhublab B, Attimarad M, Harsha S. Basic considerations in the dermatokinetics of topical formulations. Brazilian Journal of Pharmaceutical Sciences. 2013;49(3):423-434
  6. 6. Alcon Laboratories, Inc. Liquid Silicon Injection. 2010. Available from: [Accessed: August 11, 2010]
  7. 7. Granuloma. Medterms Online Medical Dictionary [Internet]. 1998. Available from: [Accessed: 20 March, 2011]
  8. 8. James DG, Williams WL. Classification of granulomatous disorders: A clinicopathological synthesis. In: James DG, Zumla A, editors. Granulomatous Disorders. United Kingdom: Cambridge Press; 1999. pp. 17-27
  9. 9. Bondurant S, Ernster V, Herdman R. Antinuclear antibodies and silicone breast implants. In: Safety of Silikon Breast Implants. Washington: The National Academy Press; 1999. pp. 198-214
  10. 10. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plastic Surgery. 2003;27:354-366. DOI: 10.1007/s00266-003-3022-1
  11. 11. Harlim A, Kanoko M, Aisah S. Classification of foreign body reaction due to industrial silicone injection. Dermatologic Surgery. 2018;9(44):1174-1182
  12. 12. Price CT, Koval KJ, Langford JR. Silicon: A review of its potential role in the prevention and treatment of postmenopausal osteoporosis. International Journal of Endocrinology. 2013;2013:316783
  13. 13. Jugdaohsingh R. Silicon and bone health. The Journal of Nutrition, Health & Aging. 2007;11(2):99-110
  14. 14. James DG. A clinicopathological classification of granulomatous disorders. Postgraduate Medical Journal. 2000;76(898):457-465
  15. 15. Agustini C, Semenzato G. Biology and immunology of granuloma. In: James DG, Zumla A, editors. Granulomatous Disorders. United Kingdom: Cambridge Press; 1999. pp. 3-16
  16. 16. Granuloma. Dorland’s Medical Dictionary [Internet]. Saunders & Elsevier. 2007. Available from: [Accessed: April 13, 2007]
  17. 17. Pollack SV. Wound healing: A review. IV. Systemic medications affecting wound healing. The Journal of Dermatologic Surgery and Oncology. 1982;8:667-672
  18. 18. Adams C, Ratner D. Composite and free cartilage grafting. Dermatologic Clinics. 2005;23:129-140, vii
  19. 19. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. Journal of the American Academy of Dermatology. 2003;48:233-237
  20. 20. Sheen JH, Sheen AP. Aesthetic Rhinoplasty. 2nd ed. St Louis: Quality Medical Publishing; 1998
  21. 21. Tardy ME. Rhinoplasty: The Art and the Science. Philadelphia: WB Saunders; 1997
  22. 22. Ellis LZ, Cohen JL, High W. Granulomatous reaction to silicone injection. The Journal of Clinical and Aesthetic Dermatology. 2012;5(7):44-47
  23. 23. Arin MJ, Bate J, Krieg T, Hunzelmann N. Silicone granuloma of face treated with minocyline. Journal of the American Academy of Dermatology. 2005;52(2):S53-S56
  24. 24. Sharma MD, Hou D, Liu Y, Koni PA, Metz R, Chandler P, et al. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to Th17-like cells in tumor-draining lymph nodes. Blood. 2009;113:6102-6111
  25. 25. Pasternack FR, Fox LP, Engler DE.Silicone granulomas treated with etanercept. Archives of Dermatology. 2005;141(1):13-15
  26. 26. Desai AM, Browning J, Rosen T. Etanercept therapy for silicone granuloma. Journal of Drugs in Dermatology. 2006;5(9):894-896
  27. 27. Styperek A, Bayers S, Beer K. Nonmedical-grade injections of permanent fillers medical and medico-legal considerations. The Journal of Clinical and Aesthetic Dermatology. 2013;6(41):20-27
  28. 28. Wheeland RG. Clinical uses of lasers in dermatology. Lasers in Surgery and Medicine. 1995;16:2-23
  29. 29. Nelson JS. An introduction to lasers and laser–tissue interactions in dermatology. In: Kaminer MS, Arndt KA, Dover JS, editors. Principles and Practices in Cutaneous Laser Surgery. 1st ed. Philadelphia: Harcourt Saunders; 2002. pp. 59-77
  30. 30. Brauner GJ. Cutaneous laser surgery: Historical perspectives. In: Kaminer MS, Arndt KA, Dover JS, editors. Principles and Practices in Cutaneous Laser Surgery. 1st ed. Philadelphia: Harcourt Saunders; 2002. pp. 3-57
  31. 31. Smit JM, Bauland CG, Winberg DS, Spauwen PHM. Pulsed dye laser treatment, a review of indication and outcomes based on published trials. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2005;58(7):981-987
  32. 32. Say Mese E, Gokhan O, Gokemir G. Treatment outcomes of long pulsed Nd:Yag laser for two different subtypes of rosacea. The Journal of Clinical and Aesthetic Dermatology. 2015;8(9):16-20

Written By

Ago Harlim

Submitted: 19 January 2019 Reviewed: 02 June 2019 Published: 22 July 2019